At the news
? NEUTRALIMPACT 2/10 144 filed Aug 12, 2026 at 16:00 ET
Director Katryn Blake filed a Form 144 to sell 2,240 shares of Twist Bioscience common stock, valued at approximately $275,250. The sale is a tax-withholding transaction tied to the settlement of a vested equity award, not a discretionary portfolio liquidation. Given the small proportional size relative to the company's $8.2B market cap and the tax-motivated nature, this filing carries minimal standalone signal for the stock.
- Director Katryn Blake filed Form 144 to sell 2,240 shares of Twist Bioscience common stock.
- The proposed sale value is approximately $275,250.
- The shares were acquired on 08/05/2026 via Restricted Stock Vesting from the issuer.
- The filing states the sale is to cover a tax obligation from the settlement of a vested equity award distribution.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access